Engineering of Escherichia coli strains for plasmid biopharmaceutical production: Scale-up challenges
Name
Prather_Engineeering of.pdf
Size
365.58 KB
Format
Adobe PDF
Checksum (MD5)
2e5f2aa8981ade49a577137f28bf59ac
Author(s)
Monteiro, Gabriel A.
Goncalves, Geisa A. L.
Prather, Kristala L. Jones
Prazeres, Duarte M. F.
Date Issued
March 2014
Journal
Vaccine
Publisher
Elsevier
Citation
Goncalves, Geisa A.L., Kristala L.J. Prather, Gabriel A. Monteiro, and Duarte M.F. Prazeres. “Engineering of Escherichia Coli Strains for Plasmid Biopharmaceutical Production: Scale-up Challenges.” Vaccine 32, no. 24 (May 2014): 2847–2850.
Version
Author's final manuscript
Abstract
Plasmid-based vaccines and therapeutics have been making their way into the clinic in the last years. The existence of cost-effective manufacturing processes capable of delivering high amounts of high-quality plasmid DNA (pDNA) is essential to generate enough material for trials and support future commercialization. However, the development of pDNA manufacturing processes is often hampered by difficulties in predicting process scale performance of Escherichia coli cultivation on the basis of results obtained at lab scale. This paper reports on the differences observed in pDNA production when using shake flask and bench-scale bioreactor cultivation of E. coli strains MG1655ΔendAΔrecA and DH5α in complex media with 20 g/L of glucose. MG1655ΔendAΔrecA produced 5-fold more pDNA (9.8 mg/g DCW) in bioreactor than in shake flask (1.9 mg/g DCW) and DH5α produced 4-fold more pDNA (8 mg/g DCW) in bioreactor than in shake flask (2 mg/g DCW). Accumulation of acetate was also significant in shake flasks but not in bioreactors, a fact that was attributed to a lack of control of pH.
MIT Department
MIT-Portugal Program
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.vaccine.2014.02.023
